As the dust settles on phase 3 data that added $45 billion to Moderna’s market cap, analysts have begun to ask a question that could define cancer care in the coming years: Can use of the vaccine be as broad as Keytruda?
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
As the dust settles on phase 3 data that added $45 billion to Moderna’s market cap, analysts have begun to ask a question that could define cancer care in the coming years: Can use of the vaccine be as broad as Keytruda?